Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this FDA Warning Letter issued to Teligent Pharma, Inc. in November 2019 concerns drug product manufacturing or quality compliance issues, though the specific nature of violations cannot be determined without access to the full letter text. As a pharmaceutical manufacturer, the company likely received this notice for violations of current good manufacturing practice (CGMP) regulations or other drug quality standards under FDA's jurisdiction. The exact regulatory scope and violation count are not specified in the available metadata, limiting the ability to characterize the severity or specific areas of non-compliance.